Patents by Inventor Alfred T. Lane

Alfred T. Lane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES
    Publication number: 20240067926
    Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.
    Type: Application
    Filed: November 3, 2023
    Publication date: February 29, 2024
    Inventors: Zurab Siprashvili, Ngon T. Nguyen, M. Peter Marinkovich, Jean Tang, Alfred T. Lane, Paul A. Khavari
  • GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES
    Publication number: 20190382724
    Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.
    Type: Application
    Filed: January 3, 2017
    Publication date: December 19, 2019
    Inventors: Zurab Siprashvili, Ngon T. Nguyen, M. Peter Marinkovich, Jean Tang, Alfred T. Lane, Paul A. Khavari
  • Production and delivery of a stable collagen
    Patent number: 9403895
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: August 2, 2016
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
  • Production and Delivery of a Stable Collagen
    Publication number: 20150232535
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Application
    Filed: April 30, 2015
    Publication date: August 20, 2015
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
  • Production and delivery of a stable collagen
    Patent number: 9040484
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: May 26, 2015
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
  • Methods and compositions for treating a subject for a lymphatic malformation
    Patent number: 8871781
    Abstract: Methods of treating lymphatic malformations using a phosphodiesterase type 5 inhibitor are provided. Pharmaceutical compositions and kits comprising phosphodiesterase type 5 inhibitors are also provided.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: October 28, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alfred T. Lane, David Berk, Anna L. Bruckner, Glenda Louise Swetman
  • Production and Delivery of a Stable Collagen
    Publication number: 20140107036
    Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.
    Type: Application
    Filed: April 26, 2012
    Publication date: April 17, 2014
    Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas